Seres Therapeutics (NASDAQ:MCRB) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Seres Therapeutics (NASDAQ:MCRB) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20), FiscalAI reports. The firm had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $0.41 million.

Seres Therapeutics Price Performance

MCRB stock traded down $0.54 during trading on Tuesday, reaching $7.15. The company had a trading volume of 51,703 shares, compared to its average volume of 61,797. Seres Therapeutics has a 52 week low of $6.53 and a 52 week high of $29.98. The company has a market cap of $68.87 million, a P/E ratio of 10.83 and a beta of 0.12. The business has a 50 day moving average of $8.69 and a 200 day moving average of $13.29.

Institutional Investors Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in Seres Therapeutics by 37.5% in the fourth quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 3,918 shares during the period. ExodusPoint Capital Management LP purchased a new stake in Seres Therapeutics in the fourth quarter worth about $190,000. OMERS ADMINISTRATION Corp purchased a new stake in Seres Therapeutics in the fourth quarter worth about $214,000. Barclays PLC grew its holdings in Seres Therapeutics by 427.8% in the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 6,024 shares during the period. Finally, State Street Corp grew its holdings in Seres Therapeutics by 14.0% in the fourth quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 4,170 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a research note on Friday, March 27th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $22.00 price target on shares of Seres Therapeutics in a research note on Friday, March 13th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $14.00.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.